

References

I-213

1. Zulresso™ (brexanolone) injection, for intravenous use. [package insert]. Sage Therapeutics. Cambridge, MA. 06/2022.
2. Kaner S, Colquhoun H, Doherty J, et al. Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression. *Hum Psychopharmacol*. 2017;32(2):e2576.
3. Curry SJ, Krist AH, Owens DK, et al. Interventions to prevent perinatal depression: US preventive services task force recommendation statement. *JAMA*. 2019; 321(6): 580-587.
4. Meltzer-Brody S, Colquhoun H, Riesenbergr R, et al. Brexanolone injection in postpartum depression: Two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. *Lancet*. 2018;392(10152):1058-1070.
5. Kaner S, Colquhoun H, Gunduz-Bruce H, et al. Brexanolone (sage-547 injection) in postpartum depression: A randomised controlled trial. *Lancet*. 2017;390(10093):480-489.
6. Leader LD, O'Connell M, Vandenberg A. Brexanolone for postpartum depression: Clinical evidence and practical considerations. *Pharmacotherapy*. 2019;39(11):1105-1112.
7. Scarff JR. Use of brexanolone for postpartum depression. *Innovations in Clinical Neuroscience*. 2019;16 (11/12):32-35.
8. Clinical Pharmacology™ 2023. Tampa FL: Gold Standard, Inc. Brexanolone.
9. Micromedex DrugDex Compendium®. 2023. Brexanolone (Zulresso).
10. Brexanolone In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated June 24, 2019.